However, although CD19 CAR‐T cell therapy could adequately deplete disease‐associated antibody‐secreting B cells and short‐term plasma cells, the price and potential risk of T cell lymphoma limit its application in this area. Here, CD19 is linked to T-cell non-Hodgkin lymphoma.